Codexis, Inc. (NASDAQ:CDXS) Shares Bought by Strs Ohio

Strs Ohio raised its position in Codexis, Inc. (NASDAQ:CDXSGet Rating) by 237.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 36,800 shares of the biotechnology company’s stock after acquiring an additional 25,900 shares during the period. Strs Ohio’s holdings in Codexis were worth $223,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of CDXS. Allspring Global Investments Holdings LLC boosted its holdings in Codexis by 44.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,018,847 shares of the biotechnology company’s stock valued at $31,576,000 after purchasing an additional 926,159 shares during the last quarter. Millennium Management LLC acquired a new position in Codexis in the 2nd quarter valued at about $9,661,000. Assenagon Asset Management S.A. boosted its holdings in Codexis by 151.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,489,025 shares of the biotechnology company’s stock valued at $15,575,000 after purchasing an additional 897,058 shares during the last quarter. FMR LLC lifted its holdings in shares of Codexis by 29.3% in the 2nd quarter. FMR LLC now owns 1,789,377 shares of the biotechnology company’s stock worth $18,717,000 after acquiring an additional 405,488 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in shares of Codexis in the 2nd quarter worth approximately $3,523,000. 93.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director John J. Nicols sold 35,716 shares of the company’s stock in a transaction that occurred on Friday, October 28th. The shares were sold at an average price of $5.53, for a total transaction of $197,509.48. Following the sale, the director now directly owns 943,106 shares of the company’s stock, valued at approximately $5,215,376.18. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Codexis news, Director John J. Nicols sold 35,716 shares of the stock in a transaction that occurred on Friday, October 28th. The shares were sold at an average price of $5.53, for a total value of $197,509.48. Following the sale, the director now directly owns 943,106 shares of the company’s stock, valued at approximately $5,215,376.18. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John J. Nicols sold 39,785 shares of the stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $5.66, for a total transaction of $225,183.10. Following the completion of the sale, the director now directly owns 863,535 shares in the company, valued at $4,887,608.10. The disclosure for this sale can be found here. Insiders have sold a total of 111,215 shares of company stock valued at $625,548 in the last ninety days. Company insiders own 7.00% of the company’s stock.

Codexis Stock Up 7.2 %

Shares of CDXS opened at $6.51 on Friday. Codexis, Inc. has a fifty-two week low of $4.21 and a fifty-two week high of $22.22. The firm’s 50 day moving average price is $5.41 and its 200 day moving average price is $6.60. The company has a market cap of $427.62 million, a P/E ratio of -13.56 and a beta of 1.47.

Codexis (NASDAQ:CDXSGet Rating) last announced its earnings results on Thursday, November 3rd. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. Codexis had a negative net margin of 23.49% and a negative return on equity of 19.59%. The firm had revenue of $34.47 million for the quarter, compared to the consensus estimate of $31.41 million. Research analysts forecast that Codexis, Inc. will post -0.56 earnings per share for the current year.

Analyst Ratings Changes

CDXS has been the topic of several recent analyst reports. HC Wainwright decreased their price objective on shares of Codexis from $25.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, November 7th. StockNews.com lowered shares of Codexis from a “hold” rating to a “sell” rating in a report on Monday, January 16th. Finally, Piper Sandler upped their price objective on shares of Codexis from $22.00 to $23.00 and gave the stock an “overweight” rating in a report on Thursday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.83.

About Codexis

(Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Recommended Stories

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXSGet Rating).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.